Relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) is challenging to treat. Outcome for such patients is dismal. A recent experimental treatment – using CD7 CAR T-cell therapy, developed by N2CR member Prof Dario Campana and the compassionate clinical use led by N2CR member Prof Allen Yeoh, were tested on 17 patients with relapsed or refractory T-ALL. Of these, 16 achieved complete remission within a month with acceptable toxicities. Eleven patients remained relapse-free after a median follow-up of 15 months. The first patient has been in remission for 55 months without needing further treatment. This breakthrough therapy offers potent anti-leukemic effects and may be a promising treatment option for relapsed/refractory T-ALL. This is being tested in the CARTALL study in NUHS.

Click here to read publication
Click here to read feature in The Straits Times. Click here to read PDF version.
Click here to read on Channel News Asia. Click here to read PDF version.